An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.
The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined with other anti-tumor therapies for perioperative treatment of resectable non-small cell lung cancer in adults.
研究概览
地位
条件
干预/治疗
- 药品:adebrelimab + SHR-A2009
- 药品:adebrelimab + SHR-A2009
- 药品:adebrelimab + SHR-A2009
- 药品:paclitaxel or pemetrexed combined with carboplatin +adebrelimab
- 药品:adebrelimab
- 药品:adebeliizumab + SHR-A2009
- 药品:adebeliizumab + SHR-A2009
- 药品:adebeliizumab + platinum-containing double chemotherapy
- 药品:almonertinib combined with SHR-A2009
- 药品:almonertinib combined with SHR-A2009
- 药品:almonertinib
- 药品:SHR-A2009 combined with almonertinib
- 药品:almonertinib monotherapy
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Yijing Chen
- 电话号码:0518-82342973
- 邮箱:yijing.chen.yc510@hengrui.com
学习地点
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510080
- Guangdong Provincial People's Hospital
-
首席研究员:
- Yilong Wu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ;
- At the time of signing the informed consent form, the age is 18-70 years old ( including both ends ), both men and women can.
- The ECOG score was 0 or 1.
- Pathologically confirmed NSCLC, assessed as resectable or previously resected (R0).
- Adequate bone marrow and organ function.
Exclusion Criteria:
- Participants who received systemic immunostimulatory therapy within 4 weeks prior to the first dose.
- Participants who received systemic immunosuppressive therapy within 2 weeks before the first dose.
- Participants with active, known or suspected autoimmune diseases.
- Other malignant tumors within 5 years before screening.
- Participants with a history of interstitial pneumonia or cannot exclude interstitial pneumonia; or there are other moderate to severe lung diseases that may affect respiratory function. Or received previous pneumonectomy surgery.
- Participants with severe cardiovascular and cerebrovascular diseases.
- There were clinically significant bleeding symptoms or obvious bleeding tendency within 1 month before the first administration.
- Arterial and venous thrombosis events occurred within 3 months before the first administration.
- HIV test positive.
- Participants with active hepatitis B or C.
1.Evidence of active tuberculosis infection within 1 year before the first administration.
12.Severe infection occurred within 4 weeks before the first administration. 13.History of severe allergic reactions to other monoclonal antibody / fusion protein drugs.
14. Allergy to any component of the treatment regimen. 15.Participants were known to have a history of psychotropic drug abuse, alcohol abuse or drug abuse.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:group A1-1adebrelimab + SHR-A2009
|
adebrelimab + SHR-A2009 adebrelimab + SHR-A2009 (longer-interval regimen arm) adebrelimab + SHR-A2009 (shorter-interval regimen arm) |
|
有源比较器:group A1-2 paclitaxel or pemetrexed combined with carboplatin +adebrelimab
|
paclitaxel or pemetrexed combined with carboplatin +adebrelimab |
|
实验性的:group1 A2-1adebrelimab + SHR-A2009 (longer-interval regimen arm)
|
adebrelimab + SHR-A2009 adebrelimab + SHR-A2009 (longer-interval regimen arm) adebrelimab + SHR-A2009 (shorter-interval regimen arm) |
|
实验性的:group2 A2-2adebrelimab + SHR-A2009 (shorter-interval regimen arm)
|
adebrelimab + SHR-A2009 adebrelimab + SHR-A2009 (longer-interval regimen arm) adebrelimab + SHR-A2009 (shorter-interval regimen arm) |
|
有源比较器:group A2-3 adebrelimab
|
adebrelimab |
|
实验性的:group1 A3-1 adebeliizumab + SHR-A2009 (longer-interval regimen arm)
|
adebeliizumab + SHR-A2009 (longer-interval regimen arm) adebeliizumab + SHR-A2009 (shorter-interval regimen arm) |
|
实验性的:group2 A3-2 adebeliizumab + SHR-A2009 (shorter-interval regimen arm)
|
adebeliizumab + SHR-A2009 (longer-interval regimen arm) adebeliizumab + SHR-A2009 (shorter-interval regimen arm) |
|
有源比较器:group A3-3 adebeliizumab + platinum-containing double chemotherapy
|
adebeliizumab + platinum-containing double chemotherapy |
|
实验性的:group B1-1 almonertinib combined with SHR-A2009 (longer-interval regimen arm)
|
almonertinib combined with SHR-A2009 (longer-interval regimen arm) almonertinib combined with SHR-A2009 (shorter-interval regimen arm) |
|
实验性的:group B1-2 almonertinib combined with SHR-A2009 (shorter-interval regimen arm)
|
almonertinib combined with SHR-A2009 (longer-interval regimen arm) almonertinib combined with SHR-A2009 (shorter-interval regimen arm) |
|
有源比较器:group B1-3 almonertinib
|
almonertinib |
|
实验性的:group B2-1 SHR-A2009 combined with almonertinib
|
SHR-A2009 combined with almonertinib |
|
有源比较器:group B2-2 almonertinib monotherapy
|
almonertinib monotherapy |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Part A1 : pCR rate;
大体时间:about 24 months
|
about 24 months
|
|
Part A2 : 2-year DFS rate;
大体时间:about 24 months
|
about 24 months
|
|
Part A3 : pCR rate and 18-month EFS rate;
大体时间:about 18 months
|
about 18 months
|
|
Part B1 : 2-year DFS rate.
大体时间:about 24 months
|
about 24 months
|
|
Part B2 : MPR rate.
大体时间:about 24 months
|
about 24 months
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
The incidence and grade of adverse events;
大体时间:about 48 months
|
about 48 months
|
|
surgical complications;
大体时间:about 24 months
|
about 24 months
|
|
EFS
大体时间:about 24 months ;
|
about 24 months ;
|
|
ORR;
大体时间:about 24 months
|
about 24 months
|
|
DFS and DFS rates;
大体时间:about 24 months
|
about 24 months
|
|
OS ;
大体时间:about 48 months
|
about 48 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.